CEP 1347

Drug Profile

CEP 1347

Alternative Names: KT 7515

Latest Information Update: 27 Mar 2008

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer Cephalon
  • Class Antiparkinsonians; Carbazoles; Indoles; Neuroprotectants; Nootropics
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Mixed-lineage kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cognition disorders; Parkinson's disease

Most Recent Events

  • 06 Feb 2008 Pharmacodynamics data from a preclinical trial in HIV-associated cognitive impairment presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)
  • 29 Jun 2006 Phase-II clinical trials in Asthma in Iceland (PO)
  • 13 Apr 2006 Data presented at the 58th Annual Meeting of the American Academy of Neurology (AAN-2006) have been added to the adverse events and Parkinson's disease and movement disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top